Apr 13, 2016

Posted by in Biotech Stocks | 0 Comments

Trend Analysis Report: Idera Pharmaceuticals Inc (NASDAQ:IDRA), Vertex Pharmaceuticals (NASDAQ:VRTX), Inovio Pharmaceuticals Inc (NASDAQ:INO)

Trend Analysis Report: Idera Pharmaceuticals Inc (NASDAQ:IDRA), Vertex Pharmaceuticals (NASDAQ:VRTX), Inovio Pharmaceuticals Inc (NASDAQ:INO)

Idera Pharmaceuticals Inc (NASDAQ:IDRA) surged +2.14% and ended at $1.91. The total traded volume was 1.84 million shares and market capitalization arrived at $226.79 million. The stock has a 52-week high price of $4.42 and its 52-week low was recorded at $1.50, while during last trade its minimum price was $1.80 and it gained the highest price of $1.92.

Idera Pharmaceuticals Inc (NASDAQ:IDRA) on March 10, 2016 reported its financial and operational results for the fourth quarter and year ended December 31, 2015.

Financial Results

Fourth Quarter Results

Net loss applicable to common stockholders for the three months ended December 31, 2015 was $12.0 million, or $0.10 per basic and diluted share, compared to a net loss applicable to common stockholders of $12.0 million, or $0.14 per basic and diluted share, for the same period in 2014. There was nominal revenue recognized in each of the fourth quarters of 2015 and 2014. Research and development expenses for the three months ended December 31, 2015 totaled $8.6 million compared to $8.2 million for the same period in 2014. General and administrative expense for the three months ended December 31, 2015 and December 31, 2014 totaled $3.7 million, respectively.

Full Year Results

Net loss applicable to common stockholders for the year ended December 31, 2015 was $48.6 million or $0.42 per diluted share, compared to net loss applicable to common stockholders of $39.2 million, or $0.47 per diluted share, for the same period in 2014. There was nominal revenue recognized during the years ended December 31, 2015 and 2014. Research and development expenses for the year ended December 31, 2015 totaled $33.7 million compared to $27.5 million for the same period in 2014. General and administrative expenses for the year ended December 31, 2015 totaled $15.4 million compared to $11.3 million for the same period in 2014.

As of December 31, 2015, our cash, cash equivalents and investments totaled $87.2 million compared to $48.6 million as of December 31, 2014.  We currently anticipate our cash position is capable of funding our operations into the third quarter of 2017.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) reported the decrease of -1.30% to close at $83.37 with the overall traded volume of 1.83 million shares. Its market capitalization on last close reached to $20.35 billion. Its beta value stands at 0.57 times. The company has the total of 246.39 million outstanding shares. Its intraday-low price was $82.54 and its hit its day’s highest price at $85.19.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on February 24, 2016 announced that it has awarded the company’s 2016 Cystic Fibrosis (CF) Circle of Care grants, totaling approximately $1 million, to 18 non-profit medical, academic, patient and community organizations. In its second year, the grants fund innovative programs to help the cystic fibrosis community. CF is a rare, life-threatening genetic disease affecting approximately 75,000 people in North America, Europe and Australia.

Despite improvements in the treatment of CF, physical and emotional support for patients and caregivers is a continuing need. Vertex’s Cystic Fibrosis Circle of Care initiative promotes collaboration and provides funding to non-profits that can enhance care and resources for people with CF.

During this year’s process, 58 proposals were received from organizations in 15 countries – a 15 percent increase in total applicants since last year. Ultimately 18 projects from Australia, Austria, Belgium, Canada, Czech Republic, France, Germany, the Netherlands and the United States were selected by a multidisciplinary group of internal and independent experts, including a CF nurse, pulmonologist and parent of a CF patient.

Inovio Pharmaceuticals Inc (NASDAQ:INO) moved up +2.76% to settle at $9.30. Its total traded volume during last trading session was 1.78 million shares. The overall market worth of this company is about $660.01 million. The 52 week range of the stock remained $4.50 – $10.83, while its day’s lowest price was $8.76 and its hit its day’s highest price at $9.34. The beta of this stock currently stands at 2.65.

Inovio Pharmaceuticals Inc (NASDAQ:INO) on March 16, 2016 announced that it has signed collaborative research agreements (CRAs) with the Wistar Institute for preventive and therapeutic DNA-based immunotherapy applications and products for cancers and infectious diseases developed by David B. Weiner, Ph.D., and his Wistar laboratory. Inovio will have the exclusive right to in-license new intellectual property developed in this collaboration. Prior to his recent move to Wistar, the underlying technology for Inovio’s DNA-based products was first developed at Dr. Weiner’s UPenn laboratory. Inovio’s license agreements for intellectual property developed at the University of Pennsylvania will not be affected.

The Wistar Institute has a storied tradition of accomplishment, global leadership, training and commercialization in the field of vaccines and immune therapies. Wistar science has achieved important health advances through the discoveries of vaccines against rubella, rotavirus, and rabies. Wistar technology resulted in the creation of hepatitis A, varicella (chickenpox), and zoster (shingles) vaccines as well as breakthrough products for the diagnosis or treatment of autoimmune, heart, and other infectious diseases.

 

Comments are closed.